• New Developments in HIV/Hepatitis C Coinfection Management and Epidemiology (Posted Feb. 6, 2009)
  From TheBodyPRO.com
• Peculiar Type of KS Emerges in Healthier Individuals (Posted Dec. 14, 2008)
  From Project Inform
• Some AIDS-Defining Conditions Now Diagnosed at Higher CD4s (Posted Dec. 14, 2008)
  From Project Inform
• Surprising Rate of Serious Heart Condition Found in Those on HAART (Posted Nov. 26, 2008)
  From Project Inform
• Impact of Testosterone Levels on Bone Mineral Density May Be More Pronounced in HIV-Infected Patients (Posted Nov. 4, 2008)
  A retrospective, controlled study of 237 patients finds that, among patients with low testosterone levels, those who are HIV infected have lower bone mineral density than those who are HIV uninfected. (An interview with Ranjani Raghunathan, M.D.)
  

  Read or listen (6 min.):

  From TheBodyPRO.com
• Continuous HAART Associated With Decreased Bone Mineral Density, SMART Substudy Finds (Posted Nov. 3, 2008)
  In one of ICAAC/IDSA 2008's most talked-about studies, a SMART substudy suggests that participants who remained on HAART continuously experienced a significantly greater reduction in bone marrow density than patients on intermittent therapy. (An interview with Birgit Grund, Ph.D.)
  

  Read or listen (7 min.):

  From TheBodyPRO.com
• Switch to Tenofovir/Emtricitabine From Abacavir/Lamivudine Appears to Halt Lipoatrophy: Gilead 934 Rollover (Posted Oct. 30, 2008)
  In a prospective rollover study from the landmark Gilead 934 trial, patients who switched NRTI combinations ceased losing fat, maintained virologic suppression and exhibited no significant change in creatinine clearance or glomerular filtration rate. (An interview with Edwin DeJesus, M.D.)
  

  Read or listen (6 min.):

  From TheBodyPRO.com
• Hospitalization Risk Similar Between HAART Responders and Nonresponders for 90 Days After Starting Therapy (Posted Oct. 28, 2008)
  The benefits of HAART initiation -- at least in terms of preventing or ameliorating illnesses that require hospitalization -- may not manifest themselves for up to three months, according to a sizeable study by Johns Hopkins University researchers. Women were more likely to be hospitalized than men, and choice of HAART regimen appeared to have no impact. (An interview with Stephen Berry, M.D.)
  

  Read or listen (11 min.):

  From TheBodyPRO.com
• Diabetes Risk Appears Lower for HIV-Infected Patients Than Uninfected Patients (Posted Oct. 27, 2008)
  A large, ongoing study of U.S. military veterans also suggests that the usual risk factors for diabetes, not HIV itself, are the main drivers of diabetes in HIV-infected people. (An interview with Adeel A. Butt, M.D.)
  

  Read or listen (5 min.):

  From TheBodyPRO.com
• HAART Use Improves Hepatitis B Vaccine Response, Even at High CD4 Counts (Posted Oct. 27, 2008)
  HIV-infected patients are approximately twice as likely to respond to hepatitis B vaccination if they are receiving antiretroviral therapy, regardless of their CD4+ cell count at the time of vaccination, according to a study by researchers with the U.S. military. (An interview with Michael Landrum, M.D.)

  Read or listen (7 min.):

  From TheBodyPRO.com
• Patients on Tenofovir/Emtricitabine May Face Higher Bone Risk From Vitamin D Insufficiency (Posted Oct. 27, 2008)
  A small study finds that, although vitamin D insufficiency is quite common among HIV-infected people, it may be a particular risk for patients receiving tenofovir/emtricitabine: These patients appear especially likely to have elevated parathyroid hormone levels, which has been associated with bone problems. (An interview with Kate Childs, M.D.)
  

  Read or listen (5 min.):

  From TheBodyPRO.com
• Switching From Combivir to Truvada Keeps HIV Undetectable, Improves Blood Fats, But Fails to Improve Limb Fat (Posted Oct. 26, 2008)
  From Project Inform
• Trend Toward Fewer AIDS-Defining Conditions Among Patients Receiving Raltegravir vs. Placebo (Posted Oct. 26, 2008)
  A new examination of 48-week BENCHMRK data found a nearly twofold reduction in AIDS-defining events among patients on raltegravir, but the findings failed to reach statistical significance. Intriguingly, greater resistance did not appear to be a predictor of AIDS-defining events. (An interview with Joseph Eron Jr., M.D.)
  

  Read or listen (7 min.):

  From TheBodyPRO.com
• Adding GM-CSF to Hepatitis B Vaccine Fails to Work (Posted Oct. 25, 2008)
  From Project Inform
• African Americans With HIV Have Higher OI Rates and Hospital Mortality, but Lower HCV Rates, Than Whites, Hospital Survey Finds (Posted Oct. 25, 2008)
  A massive, nationwide hospital survey reveals that black, hospitalized HIV-infected patients experience greater morbidity and mortality than their white counterparts -- but also appear less likely to be coinfected with hepatitis C. (An interview with Christine Oramasionwu, Pharm.D.)
  

  Read or listen (3 min.):

  From TheBodyPRO.com
• Meningococcal Vaccine Appears Safe in Youth With HIV (Posted Oct. 25, 2008)
  From Project Inform

The Body PRO's coverage of the 48th Annual ICAAC®/IDSA 46th Annual Meeting (ICAAC®/IDSA 2008) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.*

For more information on ICAAC®/IDSA 2008, please visit the conference's Web site. You may also view the conference program planner online.

*ICAAC® is a registered trademark of the American Society for Microbiology Corporation. Neither Body Health Resources Corporation nor its corporate parent, The HealthCentral Network, Inc. is affiliated with the ICAAC Conference or the American Society for Microbiology Corporation.